| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/10/2004 | WO2004004756A8 Use of pthrp antagonists for treating renal cell carcinoma |
| 06/10/2004 | WO2004004698A3 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
| 06/10/2004 | WO2004003235A3 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 06/10/2004 | WO2004003145A3 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/10/2004 | WO2004000225A3 Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| 06/10/2004 | WO2003087307A3 Use of interleukin-19 to treat cervical cancer |
| 06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003074060A8 Dna demethylase antisense and chemotherapy combination |
| 06/10/2004 | WO2003072027A3 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003066005A3 Ansamycins having improved pharmacological and biological properties |
| 06/10/2004 | WO2003064626A3 Double-stranded oligonucleotides |
| 06/10/2004 | WO2003048116A3 Esters and amides as ppar-alpha agonists ____________ |
| 06/10/2004 | WO2003040170A9 Antibodies to cd40 |
| 06/10/2004 | WO2003037258A3 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |
| 06/10/2004 | WO2003015711A3 Combination motif immune stimulatory oligonucleotides with improved activity |
| 06/10/2004 | WO2003013603A8 Modulators of p-selectin glycoprotein ligand 1 |
| 06/10/2004 | WO2003007800A9 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 06/10/2004 | WO2002090600A3 A method for regulating immune function in primates using the foxp3 protein |
| 06/10/2004 | WO2002040629A3 Promoters exhibiting endothelial cell specificity and methods of using same |
| 06/10/2004 | WO2002038168A3 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 06/10/2004 | US20040111760 Production of stilbenes in transgenic plants and the method of producing thereof |
| 06/10/2004 | US20040110956 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| 06/10/2004 | US20040110945 Very Late Antigen (Vla-4); such as 4-((4S)-fluoro-1-(2-phenylamino-6-benzoxazolylacetyl)-(2S)-pyrrolidinylmethoxy)benzoic acid; for treatment of inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, and diabetes |
| 06/10/2004 | US20040110935 Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| 06/10/2004 | US20040110928 Peptide conjugates for drug delivery |
| 06/10/2004 | US20040110920 Novel g protein-coupled receptor protein and dna thereof |
| 06/10/2004 | US20040110846 Perylenequinones for use with immunotherapy agents |
| 06/10/2004 | US20040110844 has a low side-effect and a high anti-tumor effect, in particular an anti-melanoma effect and an anti-leukemia cell effect; and is very low pungent, stimulatory and preinflammatory effect |
| 06/10/2004 | US20040110831 Urokinase inhibitors |
| 06/10/2004 | US20040110824 2-Phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 06/10/2004 | US20040110823 Bone disorders; cardiovascualr disorders; hormone replacement therapy |
| 06/10/2004 | US20040110810 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. |
| 06/10/2004 | US20040110809 di- and tricycle-substituted imidazolidine-, oxazolidine- and thiazolidine diones and thiones, e.g., 5-[p-(quinolin-3-yl)-alpha-hydroxybenzyl]-5-methylimidazolidinedione |
| 06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
| 06/10/2004 | US20040110801 Prevention of degenerative joint diseases, rheumatoid arthritis, osteoarthritis, ulcerative colitis, irritable colon and Crohn's diseas, antitumor agents; drug mixture for transdermal drug delivery, sustained release; chemical synthesis |
| 06/10/2004 | US20040110798 A pyridyl-2yl-4-[1,2,3-triazole] derivatives therapeutic agent for treating cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, hyperplasia, restenosis, skin disorders |
| 06/10/2004 | US20040110797 Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
| 06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
| 06/10/2004 | US20040110792 Methods for assessing and treating leukemia |
| 06/10/2004 | US20040110790 A flavonoids, anticarcinogenic agents for treating cancer, such as catechin, epigallocatichin-3-gallate |
| 06/10/2004 | US20040110782 Nitro and amino substituted heterocycles as topoisomerase I targeting agents |
| 06/10/2004 | US20040110779 Hydantoin derivsatives with affinity for somatostatin receptors |
| 06/10/2004 | US20040110775 Cyclin dependent kinase inhibiting purine derivatives |
| 06/10/2004 | US20040110773 Pyrimido compounds having antiproliferative activity |
| 06/10/2004 | US20040110772 Inhibitors of nucleoside phosphorylases and nucleosidases |
| 06/10/2004 | US20040110770 Cyclin-dependent kinases (CDK); Cdc2/cyclin B (CDK-1) enzymatic complex; 1,3-dihydro-3-(imidazol-4-ylmethylene)-5-(pyrid-3-yl)-2H-indolin-2-one for example; antitumor agent |
| 06/10/2004 | US20040110769 Antitumor agents for cancer treatment; 5-(3-chlorophenyl)-alpha-(4-chlorophenyl)-alpha-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine with tamoxifen for example |
| 06/10/2004 | US20040110768 (S)-3-(1H-indol-3-yl)-N-(1-methoxymethyl-cyclohexylmethyl)-2-methyl-2-[4-(4-nitro-phenyl)-oxazol-2-ylamino]-propionamide for example; cancer, psychological disorders, sexual disorders, eating disorders, inflammatory bowel disease, sleep disorders |
| 06/10/2004 | US20040110760 Nitro and amino substituted topoisomerase agents |
| 06/10/2004 | US20040110759 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 06/10/2004 | US20040110756 Anthracene-9-yl-[4-(4-nitro-phenyl)-piperazine-1-yl]-methanone for example; antitumor agents for benign and malignant tumors |
| 06/10/2004 | US20040110752 2-amino-5-((hetero)aryl)-thiazole derivatives; treatment of disorders such as cancer, immunologic disorders and allergic disorders, optionally in combination with other drugs such as immunosuppressants |
| 06/10/2004 | US20040110744 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 06/10/2004 | US20040110741 Substituted pyrazolyl compounds for the treatment of inflammation |
| 06/10/2004 | US20040110737 Complex derivatives of bis(2-acetylpyridinethiosemicarbazonato-N1,N2,S)gallium(III) as anticarcinogenic agents |
| 06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 06/10/2004 | US20040110727 Administering inhibitor of aldehyde detoxifying agent, such as buthionine sulphoximine or crotonaldehyde to treat cancer; hydrolysis by esterase |
| 06/10/2004 | US20040110725 Pyridazines as interleukin-1beta converting enzyme inhibitors |
| 06/10/2004 | US20040110723 Modified psma ligands and uses related thereto |
| 06/10/2004 | US20040110718 Anti-HCV nucleoside derivatives |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110712 Methods for treating patients and identifying therapeutics |
| 06/10/2004 | US20040110704 Decreased or deleted activity of enzyme with modified sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in reducing end; antitumor agents, cardiovascular disorders, autoimmune diseases |
| 06/10/2004 | US20040110695 Phospholipid vesicle having exogenous antigen orpolynucleic acid coding for antigen; adapted to be phagocytosed by antigen presenting cells |
| 06/10/2004 | US20040110690 Transporter peptide capable of translocating across biological membrane of pancreatic B-cells, hepatocytes, colon cells, muscle cells and/or lung cells; drug delivery; biochemical conjugation |
| 06/10/2004 | US20040110689 Methods for treating hormone associated conditions using a combination of LHRH antagonists and specific estrogen receptor modulators |
| 06/10/2004 | US20040110685 Scatter factor/hepatocyte growth factor antagonist NK4 for the treatment of glioma |
| 06/10/2004 | US20040110677 Stimulating differentiation in growth of osteoblasts and osteoclasts; wound healing of bone fractures and de novo bone formation; osteoporosis; bone cancer treatment; polynucleotide encoding polypeptide; genetic engineering |
| 06/10/2004 | US20040110674 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 06/10/2004 | US20040110668 Nucleic acid sequences differentially expressed in cancer tissue |
| 06/10/2004 | US20040110662 Administering cytotoxic agent and heat shock protein 90 inhibitors such as ansamycins for synergistic growth inhibitors of cells. This therapy as cytotoxic agent and as cell growth inhibitors |
| 06/10/2004 | US20040110282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| 06/10/2004 | US20040110236 comprises administering the hepatocytes or plasma cells or T cells to an animal after stimulation in vitro |
| 06/10/2004 | US20040110219 Detecting amount of nucleic acid encoding UKW polypeptide through hybridization and comparing with a predetermined standard value |
| 06/10/2004 | US20040110180 Comprises enzymatic polypeptide for diagnosis, treatment and prevention of cardiovascular, immune system, nervous system, lipid and cell proliferative disorders; drug screening |
| 06/10/2004 | US20040110165 Viral chemokine-antigen fusion proteins |
| 06/10/2004 | US20040110164 L-methionine $g(g)-lyase with modified function |
| 06/10/2004 | US20040110131 Thrombospondin-1 type 1 repeat polypeptides |
| 06/10/2004 | US20040109907 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 06/10/2004 | US20040109905 Method and composition of anthocyanin-rich berry extracts that prevents or inhibits angiogenesis and helicobacter pylori and acts as a powerful antioxidant that provides various health benefits |
| 06/10/2004 | US20040109904 Plant extracts; Chinese herbs ; synergistic with radiotherapy or drugs |
| 06/10/2004 | US20040109878 Removal cancer, organ transplant and autoimmune cells from bone marrow, blood |
| 06/10/2004 | US20040109877 Rna viruses; attenuation influenza virus |
| 06/10/2004 | US20040109867 Prodrugs of CC-1065 analogs |
| 06/10/2004 | US20040109866 Immonotherapy complex containing antigen, antibodies, epitopes; binding to receptors |
| 06/10/2004 | US20040109865 Antibody composition-containing medicament |
| 06/10/2004 | US20040109857 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 06/10/2004 | US20040109846 Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 06/10/2004 | US20040108086 Using Ecteinascidin- 743 drug alone or as part of synergistic mixture |
| 06/10/2004 | CA2691447A1 Ca ix-specific inhibitors |
| 06/10/2004 | CA2507273A1 Synergistic anti-cancer composition comprising alpha-ketoglutaric acid, an azonmetnhine former, and n-acetyl-seleno-methionine |
| 06/10/2004 | CA2506948A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | CA2506895A1 Cannabinoid receptor ligands |
| 06/10/2004 | CA2506796A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors |
| 06/10/2004 | CA2506310A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 06/10/2004 | CA2506037A1 Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| 06/10/2004 | CA2502970A1 Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |